| Literature DB >> 32801028 |
Brendan O'Kelly1, Ana Rueda-Benito2, Mary O'Regan3, Katherine Finan4.
Abstract
OBJECTIVES: Hospitalisations with community-acquired pneumonia (CAP) are often not managed in accordance with antimicrobial guidelines. This study aimed to assess whether guideline-driven antimicrobial prescribing for CAP can be improved using an intervention bundle. Secondary measures assessed were hospital length of stay (LOS), mortality, duration of intravenous antibiotics and total antibiotics, improved uptake of appropriate investigations, and documentation of CURB-65 score.Entities:
Keywords: Antimicrobial stewardship; Community-acquired pneumonia; Mobile audience response system
Mesh:
Substances:
Year: 2020 PMID: 32801028 PMCID: PMC7422825 DOI: 10.1016/j.jgar.2020.07.021
Source DB: PubMed Journal: J Glob Antimicrob Resist ISSN: 2213-7165 Impact factor: 4.035
Current British Thoracic Society (BTS) guidelines for empirical treatment of community-acquired pneumonia.
| CURB-65 score | First-line | Non-type 1 hypersensitivity reaction to penicillin | Type 1 hypersensitivity |
|---|---|---|---|
| 0–1 | Amoxicillin p.o. 1 g t.i.d. | Clarithromycin p.o. 500 mg b.i.d. | Clarithromycin p.o. 500 mg b.i.d. |
| 2 | Amoxicillin p.o./i.v. 1 g t.i.d. + clarithromycin 500 mg b.i.d. (i.v. if NPO) | Cefuroxime p.o. 500 mg b.i.d. or i.v. 1.5 g t.i.d. + clarithromycin 500 mg b.i.d. (i.v. if NPO) | Clarithromycin 500 mg b.i.d. (i.v. if NPO) or doxycycline 200 mg q.d. |
| 3 | Amoxicillin/clavulanic acid i.v. 1.2 g t.i.d. + clarithromycin 500 mg b.i.d. | Cefuroxime i.v. 1.5 g t.i.d. + clarithromycin 500 mg b.i.d. (i.v. if NPO) | Microbiology advice |
p.o., oral; t.i.d., three times daily; b.i.d., twice daily; i.v., intravenous; NPO, nil by mouth; q.d., once daily.
Antimicrobial choice is directed by severity of infection measured by CURB-65 score. CURB-65: confusion, urea ≥7.0 mmol/L, respiratory rate >30 breaths/min, systolic blood pressure ≤90 mmHg/diastolic blood pressure ≤60 mmHg, age >65 years old; a single point is attributed to each criterion fulfilled.
Fig. 1Distribution of CURB-65 scores in unscheduled admissions with community-acquired pneumonia as the primary diagnosis.
Baseline demographics and results of baseline laboratory and chest radiography findings.
| Characteristic | Total ( | Pre-intervention ( | Post-intervention ( | |
|---|---|---|---|---|
| Female sex [ | 37 (53.6) | 20 (54) | 17 (53) | 0.93 |
| Age (years) [median (IQR)] | 78 (68.5–86) | 80 (69.5–86) | 76.5 (68.5–85) | 0.43 |
| NH resident ( | 11 | 7 | 4 | 0.46 |
| CURB-65 score (mean ± S.D.) | 2.16 ± 1.17 | 2.03 ± 1.22 | 2.21 ± 1.01 | 0.48 |
| Co-morbidities ( | ||||
| COPD | 16 | 8 | 8 | |
| Asthma | 4 | 3 | 1 | |
| Bronchiectasis | 2 | 1 | 1 | |
| ILD | 1 | 0 | 1 | |
| Alpha-1 antitrypsin deficiency | 1 | 0 | 1 | |
| Pulmonary sarcoid | 1 | 1 | 0 | |
| Pulmonary TB (treated) | 1 | 1 | 0 | |
| Farmer’s lung | 1 | 0 | 1 | |
| Lobectomy | 1 | 1 | 0 | |
| HTN | 15 | 6 | 9 | |
| Atrial fibrillation | 9 | 5 | 4 | |
| IHD | 8 | 5 | 3 | |
| CHF | 5 | 3 | 2 | |
| CKD (eGFR < 30 mL/min/1.73 m2) | 4 | 2 | 2 | |
| T2DM | 8 | 4 | 4 | |
| Dementia | 8 | 5 | 3 | |
| Prior malignancy | 10 | 6 | 4 | |
| Stroke | 4 | 3 | 1 | |
| Epilepsy | 3 | 2 | 1 | |
| Investigations | ||||
| CRP (mg/L) [median (IQR)] | 70 (27–127) | 59 (20.5–169) | 71 (35–115) | |
| WBC count ×109cells/L [median (IQR)] | 11 (8.5–14.4) | 11.1 (7.7–14.4) | 11 (8.8–14.2) | |
| Consolidation on chest radiography ( | ||||
| Right | 36 | 19 | 17 | |
| Left | 20 | 11 | 9 | |
| Bilateral | 13 | 7 | 6 | |
IQR, interquartile range; NH, nursing home; S.D., standard deviation; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; TB, tuberculosis; HTN, hypertension; IHD, ischaemic heart disease; CHF, congestive heart failure, CKD, chronic kidney disease, eGFR, estimated glomerular filtration rate; T2DM, type 2 diabetes mellitus; CRP, C-reactive protein; WBC, white blood cell.
Includes percutaneous coronary intervention, coronary artery bypass grafting and myocardial infarction.
Includes prostate cancer, Mantle cell lymphoma, colorectal cancer, oesophageal cancer, breast cancer, renal cell carcinoma and lung cancer.
Results of primary and secondary outcomes.
| Total ( | Pre-intervention ( | Post-intervention ( | ||
|---|---|---|---|---|
| Compliance with antimicrobial guideline | 8 (21.6%) | 20 (62.5%) | <0.001 | |
| β-Lactam/β-lactamase inhibitor | 11/34 (32.4%) | 21/30 (70.0%) | 0.002 | |
| Clarithromycin | 15/29 (51.7%) | 19/25 (76.0%) | 0.065 | |
| Investigations | ||||
| Streptococcal urinary antigen | 20 | 7 (18.9%) | 13 (40.6%) | 0.024 |
| Legionella antigen | 17 | 7 (18.9%) | 10 (31.3%) | 0.14 |
| Sputum culture | 17 | 7 (18.9%) | 10 (31.3%) | 0.14 |
| Blood cultures | 47 | 27 (84.4%) | 20 (62.5%) | 0.35 |
| CURB-65 documentation | 17 | 2 (5.4%) | 15 (46.9%) | <0.001 |
| SIRS documentation | 10 | 4 (10.8%) | 6 (18.8%) | 0.35 |
| Antibiotic duration (days) [median (IQR)] | ||||
| i.v. antibiotics | 4 (2–4.5) | 4 (2–5) | 0.70 | |
| Total antibiotics | 9 (7–11) | 7 (6.5–9) | 0.01 | |
| Time to antibiotics (mean) | – | 142 min | ||
| Deaths | 5 | 2 (5.4%) | 3 (9.3%) | 0.53 |
| Length of stay (days) [median (IQR)] | 4 | 4 (3–11) | 4 (3–7) | 0.85 |
NOTE: Data are n (%) unless otherwise stated.
SIRS, systemic inflammatory response syndrome; IQR, interquartile range; i.v., intravenous.
CURB65: confusion, urea ≥7.0 mmol/L, respiratory rate >30 breaths/min, systolic blood pressure ≤90 mmHg/diastolic blood pressure ≤60 mmHg, age >65 years old; a single point is attributed to each criterion fulfilled.
Temperature >38 or <36 °C, heart rate >90 beats/min, tachypnoea >22 breaths/min, white blood cell count >12 or <4 × 109 cells/L; any criterion fulfilled scores 1 point, and ≥2 points indicate possible sepsis.
Organisms identified and proportion of positive investigations.
| Organism | Streptococcal urinary antigen | Legionella urinary antigen | Sputum cultures | Blood cultures | |
|---|---|---|---|---|---|
| Positive [ | 3/20 (15%) | 0/17 (0%) | 4/17 (23.5%) | 4/27 (14.8%) | 11/69 (16%) |
| 3 | 1 | 4 | |||
| Alpha-haemolytic | 1 | 1 | |||
| 1 | 1 | ||||
| 1 | 1 | ||||
| 1 | 1 | ||||
| 2 | 2 | ||||
| 1 | 1 |
Although E. coli is not a typical cause of community-acquired pneumonia (CAP) and secondary bacteraemia, no other source of infection was identified. The patient had no pyuria or bacteriuria and no intra-abdominal focus was seen on computed tomography (CT) of the abdomen and pelvis. The presence of unilateral consolidation on presentation and symptoms of lower respiratory tract infection lead to the diagnosis of CAP.
Number of antibiotic prescription pre- and post-intervention.
| Antibiotic | Pre-intervention | Post-intervention | Total |
|---|---|---|---|
| Clarithromycin | 15 | 19 | 34 |
| Amoxicillin | 1 | 6 | 7 |
| Amoxicillin/clavulanic acid | 22 | 19 | 41 |
| Piperacillin/tazobactam | 7 | 1 | 8 |
| Cefuroxime | 4 | 3 | 7 |
| Ceftriaxone | 0 | 1 | 1 |
| Gentamicin | 3 | 0 | 3 |
| Metronidazole | 1 | 0 | 1 |
| Levofloxacin | 0 | 1 | 1 |
A significant reduction in the use of piperacillin/tazobactam and gentamicin was seen as well as an increase in the use of amoxicillin.
Fig. 2Time to antibiotics relative to CURB-65 score in the prospective study. Kruskal–Wallis testing reached significance (P = 0.021).
Individual β-lactam antimicrobial prescriptions pre- and post-intervention.
NOTE: Blue boxes indicate non-compliance with the guidelines. Ceftriaxone was used in one case with community-acquired pneumonia as a secondary diagnosis with intra-abdominal infection as the primary diagnosis; this was deemed appropriate in that setting. No other episodes had apparent underlying factors that accounted for deviation from guidelines.
Co-amoxiclav, amoxicillin/clavulanic acid; TZP, piperacillin/tazobactam.